

Diabetic Macular Edema

A Study to Investigate RO7200220 in Diabetic Macular Edema

A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema

Trial Status Active, not recruiting	Trial Runs In 9 Countries	Trial Identifier NCT05151731 2021-003756-16 BP43445
---	-------------------------------------	--

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

Study BP43445 is a phase II, multicenter, randomized, double-masked, active comparator-controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of vamikibart administered intravitreally in participants with diabetic macular edema. Only one eye will be chosen as the study eye. The duration of the study will be up to 76 weeks.

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT05151731 2021-003756-16 BP43445
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No
